Business Context and Reporting Period
This Form 8-K is filed by IMARA Inc. (not Enliven Therapeutics, Inc., as noted in the metadata) on March 15, 2022. The filing serves to announce the Company's financial results for the fiscal year ended December 31, 2021, along with other business highlights. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover page and index for the 8-K filing and does not contain specific numerical data. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in the filing text.
- Profit/Loss: Not provided in the filing text.
- Cash Flow: Not provided in the filing text.
- Margins: Not provided in the filing text.
- Debt and Liquidity: Not provided in the filing text.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. It only references the announcement of the 2021 results.
Guidance, Outlook, and Risks
The text does not include specific guidance, outlook, management commentary, or risk factors. It notes that the press release (Exhibit 99.1) contains the full text of the announcement but explicitly states that the information in Item 2.02 and the exhibit is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the correct registrant name is IMARA Inc. (Ticker: IMRA), not Enliven Therapeutics, Inc.
- Review Exhibit 99.1 (the Press Release) for actual financial figures, as they are not present in the 8-K cover text.
- Confirm the fiscal year covered is ended December 31, 2021.
- Note that the financial information in this specific filing is not deemed "filed" under Section 18 of the Exchange Act.